Faraoni I, Graziani G, Turriziani M, Masci G, Mezzetti M, Testori A, Veronesi U, Bonmassar E
Department of Neurosciences, University of Rome Tor Vergata, Italy.
Lab Invest. 1999 Aug;79(8):993-1005.
Telomerase is a ribonucleoprotein complex with reverse-transcriptase activity responsible for telomere reconstitution. High telomerase activity was found in cancer cells, but not in differentiated homologous nonmalignant tissues. We demonstrated previously that the disappearance of telomerase activity is a reliable marker of tumor cell killing in human cancer cell lines. We have investigated the possibility of evaluating chemosensitivity of neoplastic cells of different origin [ovary, lung, breast, gastrointestinal, skin (melanoma)] obtained from cancer patients, by measuring residual telomerase activity after drug treatment in vitro. Using the classical telomeric repeat amplification protocol ("TRAP") assay based on polymerase chain reaction, we examined telomerase activity of untreated or drug-treated tumor cell suspensions, derived from the processing of surgical specimens. Feasibility and reproducibility of the assay were evaluated according to various parameters, including drug concentration, time of in vitro culture, and type of tumor. The results indicated that the assay is highly sensitive and reproducible, and can be performed using surgical specimens in a reasonable percentage of cases, ranging from 40% (breast cancer) to 100% (ovarian cancer). Moreover, the assay provides comparable results using a wide range of tumor cells, and the presence of normal cells does not interfere with the results. Prolonged tumor cell culture is not required because the assay can be completed within 24 to 72 hours after sample collection. In conclusion, the present investigation provides the technical bases for future studies to evaluate whether this assay would be able to predict patient's response to antitumor agents.
端粒酶是一种具有逆转录酶活性的核糖核蛋白复合物,负责端粒的重建。在癌细胞中发现了高活性的端粒酶,而在分化的同源非恶性组织中则未发现。我们之前证明,端粒酶活性的消失是人类癌细胞系中肿瘤细胞杀伤的可靠标志物。我们研究了通过测量体外药物治疗后残留的端粒酶活性,来评估从癌症患者获取的不同来源[卵巢、肺、乳腺、胃肠道、皮肤(黑色素瘤)]肿瘤细胞的化疗敏感性的可能性。使用基于聚合酶链反应的经典端粒重复序列扩增协议(“TRAP”)分析法,我们检测了来自手术标本处理的未处理或药物处理的肿瘤细胞悬液的端粒酶活性。根据各种参数,包括药物浓度、体外培养时间和肿瘤类型,评估了该分析方法的可行性和可重复性。结果表明,该分析方法高度灵敏且可重复,在相当比例的病例中可以使用手术标本进行检测,比例范围从40%(乳腺癌)到100%(卵巢癌)。此外,该分析方法使用广泛的肿瘤细胞可提供可比的结果,并且正常细胞的存在不会干扰结果。不需要长时间的肿瘤细胞培养,因为该分析可以在样本采集后24至72小时内完成。总之,本研究为未来评估该分析方法是否能够预测患者对抗肿瘤药物的反应的研究提供了技术基础。